Lyon, France, September 27, 2023 – 6:00 p.m. CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), an advanced clinical-stage biotechnology company, leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving patient survival with cancer, today announced that two abstracts have been accepted for presentation, in poster form, at the 38th annual conference of the Society for Immunotherapy of Cancer (SITC), a leading global event in immunotherapy, which will be held from November 1 to 5, 2023 in San Diego, California, United States. This is the first time that the Company will present non-clinical data in immuno-oncology, and in particular its selection approach using artificial intelligence (AI) and in vitro results for the first product in its new range, MaaT03X, dedicated to improve patient response to immunotherapies in solid tumors.
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]